A Phase 1 Study of LNCB74 in Advanced Solid Tumors (NCT06774963)
A Phase 1, Open-label, Dose Escalation and Dose Expansion Study for LNCB74, a B7-H4 Targeted Antibody Drug Conjugate, as Monotherapy in Participants With Advanced Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.
Who can join: Review the eligibility criteria below.
Location: Hoag Family Cancer Institute — Newport Beach, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (14 Sites)
- Hoag Family Cancer Institute — Newport Beach, California
- St. Elizabeth Healthcare — Edgewood, Kentucky
- Dana Farber Cancer Institute — Boston, Massachusetts
- Washington University, Siteman Cancer Center — St Louis, Missouri
- John Theurer Cancer Ctr at Hackensack Univ. Med Ctr. — Hackensack, New Jersey
- Roswell Park Comprehensive Cancer Center — Buffalo, New York
- Cleveland Clinic Taussig Cancer Institute — Cleveland, Ohio
- Sidney Kimmel Comprehensive Center at Jefferson — Philadelphia, Pennsylvania
- UPMC — Pittsburgh, Pennsylvania
- MD Anderson — Houston, Texas
- NEXT Oncology — San Antonio, Texas
- UT Health San Antonio - MD Anderson Cancer Center — San Antonio, Texas
- Intermountain/LDS Hospital Ph 1 Research Program — Salt Lake City, Utah
- Inova Schar Cancer Institute — Falls Church, Virginia
📞 Contact the Study Coordinator
Phone: (949) 764-7110
Email: Holland.Orndorff@hoag.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Ovarian Cancer
- Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy — New York, New York
- Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer — Pittsburgh, Pennsylvania
- Trial on Radical Upfront Surgery in Advanced Ovarian Cancer — New York, New York
- Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) — Duarte, California
- Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) — Little Rock, Arkansas
- NeoVax With Nivolumab in Patients With Ovarian Cancer — Boston, Massachusetts
Explore by condition: All Ovarian Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.